SCHEMBL3229914

SCHEMBL3229914

CN(c1cc(-c2ccccc2)nc(Cl)n1)C(C)(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.59
KMT2A Q03164 8/20 0.59
L3MBTL1 Q9Y468 5/20 0.59
ALDH1A1 P00352 5/20 0.59
HPGD P15428 3/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
KDM4E B2RXH2 5/20 0.58
MAPT P10636 4/20 0.58
TDP1 Q9NUW8 3/20 0.58
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
LMNA P02545 2/20 0.39
TSHR P16473 1/20 0.39
ATM Q13315 1/20 0.39
ADORA1 P30542 3/20 0.38
ADORA2A P29274 1/20 0.38
PKM P14618 2/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL782567 0.76 MEN1 (1.00) MEN1KMT2AL3MBTL1ALDH1A1HPGD
SCHEMBL3261298 0.74 MEN1 (0.51) MEN1KMT2AL3MBTL1ALDH1A1HPGD
SCHEMBL24212278 0.73 MEN1 (0.91) MEN1KMT2AL3MBTL1ALDH1A1HPGD
SCHEMBL13728744 0.73 MEN1 (0.91) MEN1KMT2AL3MBTL1ALDH1A1HPGD
SCHEMBL16161050 0.73 MEN1 (0.91) MEN1KMT2AL3MBTL1ALDH1A1HPGD
SCHEMBL10051514 0.73 MEN1 (0.91) MEN1KMT2AL3MBTL1ALDH1A1HPGD
SCHEMBL30939448 0.73 MEN1 (0.91) MEN1KMT2AL3MBTL1ALDH1A1HPGD
SCHEMBL632215 0.72 MEN1 (0.73) MEN1KMT2AL3MBTL1ALDH1A1HPGD
SCHEMBL413907 0.71 MEN1 (0.79) MEN1KMT2AL3MBTL1ALDH1A1HPGD
SCHEMBL3220814 0.71 MEN1 (0.59) MEN1KMT2AL3MBTL1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
WO-2010028179-A1 HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-11 WO disclosed
WO-2010028179-A1 HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS GATAD2B, GATAD2A, RUNX1 MEN1 1320/4885KMT2A 739/4885L3MBTL1 3769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.